Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Ambrx, Inc.
Scientific Title
A Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 Expression